Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genfit S.A. ADR (GNFT)

Genfit S.A. ADR (GNFT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 182,396
  • Shares Outstanding, K 49,835
  • Annual Sales, $ 41,320 K
  • Annual Income, $ -31,270 K
  • 60-Month Beta 1.08
  • Price/Sales 4.11
  • Price/Cash Flow N/A
  • Price/Book 2.43
Trade GNFT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.40 +2.94%
on 04/19/24
3.80 -7.89%
on 04/04/24
-0.18 (-4.89%)
since 03/22/24
3-Month
3.40 +3.07%
on 03/14/24
4.04 -13.37%
on 01/30/24
-0.39 (-10.03%)
since 01/23/24
52-Week
2.89 +20.96%
on 10/09/23
4.75 -26.32%
on 06/21/23
-0.26 (-6.91%)
since 04/21/23

Most Recent Stories

More News
Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

/PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has...

GNFT : 3.50 (-4.37%)
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille, France; Cambridge, MA; July 08, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives...

GNFT : 3.50 (-4.37%)
GENFIT: May 25, 2022 Combined Shareholders Meeting results

Quorum of 25.16% on first convening; allowing approval of all the resolutions submitted by the Board of Directors Lille, France; Cambridge, MA; May 25,...

GNFT : 3.50 (-4.37%)
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)

Cash and cash equivalents totaled €222.2 million as of March 31, 2022 Lille, France; Cambridge, MA; May 11, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a...

GNFT : 3.50 (-4.37%)
GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022

Lille, France; Cambridge, MA; April 29, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives...

GNFT : 3.50 (-4.37%)
GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents

Lille, France; Cambridge, MA; April 20, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives...

GNFT : 3.50 (-4.37%)
What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock

GENFIT S.A. Unsponsored ADR (GNFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GNFT : 3.50 (-4.37%)
GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update

Cash and cash equivalents totaled €258.8 million as of December 31, 2021Major financial achievements in 2021 include landmark strategic partnership deal...

GNFT : 3.50 (-4.37%)
GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021

Cash and cash equivalents totaled €258.8 million as of December 31, 2021, which includes the €120 million upfront payment and a €28 million equity...

GNFT : 3.50 (-4.37%)
GENFIT: 2022 Financial Calendar

Lille, France; Cambridge, MA; January 24, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...

GNFT : 3.50 (-4.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France....

See More

Key Turning Points

3rd Resistance Point 4.05
2nd Resistance Point 3.88
1st Resistance Point 3.77
Last Price 3.50
1st Support Level 3.49
2nd Support Level 3.32
3rd Support Level 3.21

See More

52-Week High 4.75
Fibonacci 61.8% 4.04
Fibonacci 50% 3.82
Fibonacci 38.2% 3.60
Last Price 3.50
52-Week Low 2.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar